SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2009 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (183)2/12/2009 2:38:45 PM
From: scaram(o)uche  Respond to of 418
 
Thanks, Peter, didn't know that.

Immunogenicity is a general issue of concern for MAb constructs.

Not saying this is a magic bullet. CD19, like CD20, is expressed on normal B cells. I'd use the construct before SCT and pray.

There's no talk of magic antigens that are restricted to malignancies, and it's an approach that will make sense to many cancer immunologists. Big difference, starting with an honest view of "cancer antigens".



To: Biomaven who wrote (183)2/12/2009 3:09:40 PM
From: Arthur Radley  Read Replies (1) | Respond to of 418
 
Peter,
Could you elaborate on the issue you raised?
How would using a subc. pump change the efficacy from the currently used infusion pump?
Should they switch to subc. dosing, how will this impact their trials......delay, raise the cost of trial, etc.

The stock today has had a wild ride...3x normal volume and most of it on the sell side, but currently it has bounced off the lows.

Thanks!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News